AUPH
Aurinia Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$16.08
−0.25%Year over year
Reported trailing growth
- Revenue
- +19.8%
- EBITDA
- +117.6%
- EBIT
- +189.8%
- EPS
- +448.8%
- Free cash flow
- +87.8%
- Operating cash flow
- +87.5%
Forward estimates
Based on analyst estimates
- Revenue
- +9.7%
- EBITDA
- -14.7%
- EPS
- -66.9%
Three-year CAGR
- Revenue
- +28.3%
- EBITDA
- +302.7%
- EBIT
- +2338.4%
- Net income
- +4893.1%
- EPS
- +5250.0%
- Free cash flow
- +207.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026